📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
NNMT Inhibitor NAD+ Amplifier

5-Amino-1MQ

5-Amino-1-methylquinolinium · NNMT Inhibitor · NAD+ Amplifier

"Not technically a peptide — a small molecule that blocks NNMT, the enzyme that consumes SAM-e and keeps NAD+ precursors locked up. Blocking NNMT raises intracellular NAD+, activates brown fat, reduces adipocyte size, and may enhance the effects of NAD+ precursors (NMN/NR) taken alongside. The fastest-growing compound in the biohacking space in 2024–25."

Type
Small molecule NNMT inhibitor · not a peptide
Target
NNMT enzyme · adipose + liver
Status
UK: not illegal to buy or possess (research compound) · WADA: not specifically listed · US FDA: not approved · no published human trials
Route
Orally bioavailable
Protocol summary
Community dose
50–150 mg/day oral
Route
Oral (large dose volume)
Cycle
6–12 weeks · then 3–6 off
Community-reported
50–150 mg/day oral · 6–12 week cycles · stacks with NMN/NR
No published human trials; community data only from biohacking community 2024–25
How we read the evidence
Strong mouse data on NNMT inhibition · zero published human trials · community protocols are extrapolation
Animal evidence

Substantial in mice. Neelakantan et al. (2019, Nature Communications) showed 5-Amino-1MQ reduced adipocyte size by 30%, increased metabolic rate, and prevented weight gain in high-fat-diet mice without food restriction. C57BL/6 mice on 11-week high-fat diet treated with 5-Amino-1MQ subcutaneously at 20 mg/kg three times daily for 11 days lost body weight. Cell-line work (3T3-L1 adipocytes) at 30 µM showed NNMT inhibition with corresponding rises in NAD+ and SAM — clean dose-response, selective on-target pharmacology.

Community & clinical practice

Community protocols converge on 50–150 mg/day orally, in 6–12 week cycles followed by 3–6 weeks off. Start at 50 mg/day, advance to 100–150 if tolerated. Oral is preferred because the dose volume required for SubQ (10–30 mL) is impractical. Take on empty stomach or low-fat meal. The cycling pattern is theoretical — no published human work establishes whether tolerance develops.

Human trial data

No published human clinical trials. All efficacy data is from cell lines and mouse models. The mechanism is well-characterised (NNMT inhibition preserves NAD+ and SAM) and the safety profile in mice is favourable, but human dose-response, real-world fat loss magnitude, and long-term safety are all unknown.

Regulatory status

Not FDA-approved. Not a peptide — small molecule (~159 g/mol), quinolinium family. Sold as a research compound. Sourcing via verified vendors with COA — purity matters more than usual because oral dose volumes are large.

Convergence

5-Amino-1MQ has the cleanest preclinical NNMT-inhibition signal in this category and a plausible mechanism for fat loss without appetite suppression. But human data does not exist — every protocol on the market is extrapolation from mouse studies. Community 50–150 mg/day is the converged dose, 6–12 week cycles the converged pattern. Pep IQ flags this honestly: the mechanism is real and interesting, the human protocol is best-guess.

Origin & Background

Blocking the NAD+ consumer — not just adding precursors

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of NNMT — nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide using S-adenosylmethionine (SAM-e) as the methyl donor. NNMT is highly expressed in adipose tissue and liver. Its activity consumes both SAM-e and nicotinamide — diverting these substrates away from NAD+ synthesis and methyl donor pathways that support epigenetic regulation.

The logical insight: rather than simply adding more NAD+ precursors (NMN or NR), what if you blocked the enzyme that wastes them? NNMT inhibition raises intracellular NAD+ by reducing nicotinamide catabolism, increases SAM-e availability (restoring methyl donor capacity for epigenetic regulation), and — critically — activates thermogenic brown-fat-like programmes in white adipocytes. This makes 5-Amino-1MQ mechanistically distinct from NMN/NR: it attacks the consumption side rather than the supply side of the NAD+ equation.

Research from the Kramer laboratory at Cornell identified 5-Amino-1MQ as a potent NNMT inhibitor in 2021, showing in obese mouse models that treatment reduced adipocyte size, activated thermogenic gene expression in fat tissue, and caused significant fat mass reduction without changes in food intake. The mechanism appeared to involve SIRT1 activation (an NAD+-dependent sirtuin) and PGC-1α upregulation — the same pathway that exercise and caloric restriction activate.

Note: 5-Amino-1MQ is included in this peptide reference because it is consistently discussed alongside peptides in the biohacking community and is commonly sourced from research peptide suppliers, despite not being a peptide itself. The mechanism — raising NAD+ and activating metabolic programmes — places it naturally alongside AICAR, NAD+/NMN, MOTS-c, and 5-Amino-1MQ in the metabolic optimisation category.

NMN/NR vs 5-Amino-1MQ: NMN and NR add nicotinamide precursors to increase NAD+ synthesis. 5-Amino-1MQ blocks NNMT, reducing NAD+ precursor catabolism. They are complementary — taking both simultaneously addresses both supply and consumption. Several community users stack all three. The combination logic is mechanistically sound; controlled trials are absent.

Science & Mechanism

NNMT inhibition — raise NAD+, activate brown fat

Mechanism of Action

1
NNMT inhibition: 5-Amino-1MQ binds NNMT's active site and blocks the methylation of nicotinamide to N1-methylnicotinamide. This reduces nicotinamide catabolism and increases the pool available for NAD+ synthesis via the salvage pathway — raising intracellular NAD+ particularly in adipose and liver tissue where NNMT is most active.
2
SAM-e restoration: NNMT consumes SAM-e (S-adenosylmethionine) as a methyl donor. Blocking NNMT increases SAM-e availability, which supports DNA methylation, histone methylation, and other epigenetic regulatory processes that decline with age and dietary deficiency.
3
Sirtuin activation (SIRT1, SIRT3): The increased intracellular NAD+ activates NAD+-dependent sirtuins — particularly SIRT1 and SIRT3. SIRT1 deacetylates PGC-1α, activating mitochondrial biogenesis, β-oxidation, and thermogenic programmes. This is the same pathway as caloric restriction and exercise-induced NAD+ elevation.
4
Brown fat activation and thermogenesis: In adipocytes, 5-Amino-1MQ treatment induces UCP1 (uncoupling protein 1) expression — the marker of brown/beige adipocyte thermogenic capacity. White adipocytes begin expressing brown fat characteristics (browning), increasing energy expenditure without changes in food intake. In obese mouse models, this produced significant reduction in fat mass.
5
Adipocyte size reduction: Beyond thermogenesis, NNMT inhibition reduced triglyceride accumulation in adipocytes in preclinical models — cells become smaller and more metabolically active. This may reflect a fundamental shift in adipocyte programming toward a more metabolically favourable phenotype.
Things to know

Risks & what we don't know

⚠️
Limited human safety data — widely used in community but formal human trials are absent. NNMT is involved in multiple metabolic pathways. The primary concern is unintended effects from reduced NNMT activity in tissues beyond adipose, and from altered SAM-e flux affecting methylation reactions. The compound appears well-tolerated in community use to date.
Unknown
Off-target NNMT inhibition — NNMT is expressed in liver, kidney, and other tissues beyond adipose. Chronic inhibition in these tissues could have effects not seen in short-term adipose-focused studies. Long-term human safety is not characterised.
Unknown
Methyl donor flux effects — increasing SAM-e availability alters global methylation balance. The long-term epigenetic implications of chronically elevated SAM-e in a 5-Amino-1MQ context are unknown.
Mild
Mild GI effects — nausea and loose stools reported at higher doses (above 100mg). Generally resolves within the first week. Starting at 25–50mg and titrating up is recommended.
Honest Assessment

Editor's summary

5-Amino-1MQ represents a genuinely novel approach to the NAD+ and metabolic health space — attacking the problem from the consumption side rather than adding precursors. The animal data is compelling: fat mass reduction without calorie restriction, brown fat activation, and SIRT1/PGC-1α pathway engagement. The mechanism is well-characterised at the molecular level.

The human evidence gap is real. Community adoption is substantial and growing, but controlled human trials are essentially absent. The compound's long-term safety profile, optimal dosing, and effects in diverse metabolic contexts are not established. That said, the community experience to date is largely positive, with the fat loss and thermogenic effects being the most consistently reported outcomes.

Verdict
"A mechanistically distinct approach to the NAD+ space — blocking consumption rather than adding supply. Strong animal data for fat loss and brown fat activation. Synergistic with NMN/NR. Orally bioavailable. The fastest-growing biohacking compound of 2024–25. Human trial data is missing but growing community experience is broadly positive."